- In July 2021, Abbott launched the PanbioTM COVID-19 antigen self-test in India to expand its quick diagnostics offering to meet screening requirements at home, work, and clinics.
- In March 2021 Roche Diagnostics announced the permission for Emergency Use Authorization (EUA) from the United States Food and Drug Administration (FDA) for the COVID-19 rapid antigen test, which is intended for use by healthcare professionals in point-of-care situations with COVID-19 patients.
Frequently Asked Questions
QIAGEN (Germany), F.Hoffmann-La Roche Ltd (Switzerland), Seegene Inc. (South Korea), SolGent Co. Ltd (South Korea), Curetis (Germany), KURBO INDUSTRIES LTD. (Japan), Devex (U.S.), Thermo Fisher Scientific Inc (U.S.), Mylab Discovery Solutions Pvt. Ltd (India), Abbott (U.S.), Getein Biotech, Inc (China), Biomaxima SA (Poland), CTK Biotech, Inc (U.S.), CDC (U.S.), BGI (China), Luminex Corporation (U.S.), Avellino.com (U.S.), PerkinElmer Inc (U.S.), Danaher (U.S.), Thermo Fisher Scientific Inc. (U.S.) are the major companies in the COVID-19 Diagnostics market.
In July 2021, Abbott launched the PanbioTM COVID-19 antigen self-test in India to expand its quick diagnostics offering to meet screening requirements at home, work, and clinics.
The countries covered in the busway market are U.S., Canada, Mexico, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, rest of Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, rest of Asia-Pacific, Saudi Arabia, U.A.E., South Africa, Egypt, Israel, rest of Middle East and Africa, Brazil, Argentina, and rest of South America.
